Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Lymphoma

Free Subscription 02.02.2026 1 Blood 1 Br J Haematol 1 Eur J Haematol 1 Haematologica 3 Leuk Lymphoma 1 Leukemia 1 N Engl J Med 1 Proc Natl Acad Sci U S A 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Blood

1. URANO Y, Satou A
   Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.
   Blood. 2026;147:602.
   PubMed        
   
   

   
   Br J Haematol

2. SONG J, Jiang H, Ding K, Liu H, et al
   Zanubrutinib, lenalidomide, rituximab, temozolomide +/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.
   Br J Haematol. 2026 Jan 26. doi: 10.1111/bjh.70335.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

3. HERNANI R, Albert E, Hernani-Morales C, Zuniga S, et al
   Microbiome-Based Modeling of CAR-T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing.
   Eur J Haematol. 2026 Jan 25. doi: 10.1111/ejh.70121.
   PubMed         Abstract available
   
   

   
   Haematologica

4. CASTONGUAY M, Seymour JF
   Transforming mantle cell lymphoma: the journey across eras.
   Haematologica. 2026 Jan 29. doi: 10.3324/haematol.2025.300275.
   PubMed         Abstract available
   
   

   
   Leuk Lymphoma

5. BANEGAS DE, Ferrarini I, Bernardelli A, Moioli A, et al
   Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
   Leuk Lymphoma. 2026 Jan 29:1-5. doi: 10.1080/10428194.2026.2621825.
   PubMed        
   
   
6. CHIRIAC R, Donzel M, Mauduit C, Gerland LM, et al
   Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.
   Leuk Lymphoma. 2026 Jan 29:1-4. doi: 10.1080/10428194.2026.2620550.
   PubMed        
   
   
7. RIBER HANSEN EV, Dennis S, Braendstrup P, Eriksen JO, et al
   Discordant cell-of-origin in refractory/relapsed LBCL at diagnosis and relapse.
   Leuk Lymphoma. 2026;67:377-384.
   PubMed         Abstract available
   
   

   
   Leukemia

8. GRAF CM, Reese M, Vicente-Luque A, Monig N, et al
   Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.
   Leukemia. 2026 Jan 26. doi: 10.1038/s41375-025-02849.
   PubMed        
   
   

   
   N Engl J Med

9. 
   Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
   N Engl J Med. 2026;394:520.
   PubMed        
   
   

   
   Proc Natl Acad Sci U S A

10. JACOBS AN, Jahn D, Beringer T, Wolf S, et al
    RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.
    Proc Natl Acad Sci U S A. 2026;123:e2534531123.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

11. JOHNSTONE P, Bressel M, Seymour JF, Juneja S, et al
    Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data.
    Radiother Oncol. 2026;217:111388.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.